• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.

作者信息

Fan Rong, Hou Jinlin

机构信息

Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Hepatology Unit, Shenzhen Hospital, Southern Medical University, Shenzhen, China.

出版信息

Aliment Pharmacol Ther. 2021 Sep;54(5):724-725. doi: 10.1111/apt.16548.

DOI:10.1111/apt.16548
PMID:34379840
Abstract
摘要

相似文献

1
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.社论：中心性肥胖是接受抗病毒治疗的亚洲慢性乙型肝炎患者肝细胞癌的危险因素——作者回复
Aliment Pharmacol Ther. 2021 Sep;54(5):724-725. doi: 10.1111/apt.16548.
2
Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy.社论：对于接受抗病毒治疗的亚洲慢性乙型肝炎患者，中心性肥胖是肝细胞癌的一个危险因素。
Aliment Pharmacol Ther. 2021 Sep;54(5):722-723. doi: 10.1111/apt.16498.
3
Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors' reply.社论：接受替诺福韦或恩替卡韦治疗的慢性乙型肝炎患者发生肝细胞癌的风险相似——来自欧洲的新线索。作者回复
Aliment Pharmacol Ther. 2021 Mar;53(5):659. doi: 10.1111/apt.16251.
4
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
Antivir Ther. 2009;14(2):139-42.
5
Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B-authors' reply.信函：慢性乙型肝炎免疫耐受期肝细胞癌的风险——作者回复
Aliment Pharmacol Ther. 2020 Sep;52(5):913-914. doi: 10.1111/apt.15992.
6
Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.接受恩替卡韦治疗慢性乙型肝炎患者中的肥胖与肝细胞癌
Clin Mol Hepatol. 2016 Sep;22(3):339-349. doi: 10.3350/cmh.2016.0021. Epub 2016 Sep 25.
7
The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.韩国慢性乙型肝炎患者恩替卡韦治疗 5 年内及 5 年后发生肝细胞癌的风险。
Liver Int. 2018 Dec;38(12):2269-2276. doi: 10.1111/liv.13938. Epub 2018 Aug 19.
8
Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.抗病毒治疗时代乙型肝炎病毒相关肝细胞癌：非病毒危险因素的新作用。
Liver Int. 2020 Oct;40(10):2316-2325. doi: 10.1111/liv.14607. Epub 2020 Aug 3.
9
Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.中心型肥胖与接受抗病毒治疗的慢性乙型肝炎患者肝细胞癌的相关性。
Aliment Pharmacol Ther. 2021 Aug;54(3):329-338. doi: 10.1111/apt.16469. Epub 2021 Jun 22.
10
Chronic hepatitis B and hepatocellular carcinoma.慢性乙型肝炎与肝细胞癌。
Clin Liver Dis. 2010 Aug;14(3):461-76. doi: 10.1016/j.cld.2010.05.009.

引用本文的文献

1
Analysis of influencing factors of concurrent primary liver cancer in hepatitis B patients and construction of column chart prediction model.乙肝患者并发原发性肝癌的影响因素分析及柱状图预测模型构建
Epidemiol Infect. 2025 Sep 16;153:e111. doi: 10.1017/S0950268825100538.